Literature DB >> 3073383

Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment.

B Legg1, M Rowland.   

Abstract

Cyclosporin (CyA) exhibits saturable binding to erythrocytes. A one-site binding model was fitted to data from renal transplant patients receiving CyA therapy. The average maximum binding capacity is 2560 micrograms CyA/liter of packed erythrocytes; the unbound CyA concentration associated with 50% saturation of the binding site is 67 micrograms/liter. Analysis indicates that whole-blood CyA measurement to monitor drug therapy should be viewed cautiously, particularly when the hematocrit varies considerably. The error in estimating absolute bioavailability at steady state from whole-blood measurements, resulting as a consequence of the saturable binding, has been explored. Although extrapolation to the therapeutic situation, which involves transient drug administration, is difficult, errors of up to 25% are anticipated. When an accurate estimate of bioavailability is required, analysis based on plasma data is proposed. For bioequivalence testing, both blood and plasma CyA data are equally acceptable.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3073383     DOI: 10.1023/a:1015932032609

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

1.  Cyclosporine serum concentrations soon after heart or heart-lung transplantation.

Authors:  S Aziz; P E Oyer; R E Kates
Journal:  J Clin Pharmacol       Date:  1986 Nov-Dec       Impact factor: 3.126

2.  The pharmacokinetics of cyclosporine A in uremic patients.

Authors:  A Lindberg; B Odlind; G Tufveson; B Lindström; J Gabrielsson
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

Review 3.  Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters.

Authors:  B D Kahan
Journal:  Transplantation       Date:  1985-11       Impact factor: 4.939

4.  Measuring cyclosporin in plasma.

Authors:  G Bandini; P Ricci; G Visani; S Tura; S Boschi
Journal:  Lancet       Date:  1983-04-02       Impact factor: 79.321

5.  Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.

Authors:  M Lemaire; J P Tillement
Journal:  J Pharm Pharmacol       Date:  1982-11       Impact factor: 3.765

6.  The pharmacokinetics of cyclosporine. II. Blood plasma distribution and binding studies.

Authors:  W M Awni; R J Sawchuk
Journal:  Drug Metab Dispos       Date:  1985 Mar-Apr       Impact factor: 3.922

7.  Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay.

Authors:  S G Carruthers; D J Freeman; J C Koegler; W Howson; P A Keown; A Laupacis; C R Stiller
Journal:  Clin Chem       Date:  1983-01       Impact factor: 8.327

8.  Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites.

Authors:  G Maurer; H R Loosli; E Schreier; B Keller
Journal:  Drug Metab Dispos       Date:  1984 Jan-Feb       Impact factor: 3.922

9.  Intravenous cyclosporine kinetics in renal failure.

Authors:  F Follath; M Wenk; S Vozeh; G Thiel; F Brunner; R Loertscher; M Lemaire; K Nussbaumer; W Niederberger; A Wood
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

10.  A radioimmunoassay to measure cyclosporin A in plasma and serum samples.

Authors:  P Donatsch; E Abisch; M Homberger; R Traber; M Trapp; R Voges
Journal:  J Immunoassay       Date:  1981
View more
  14 in total

1.  Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses.

Authors:  M O Karlsson; A Lindberg-Freijs
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

3.  Use of dried blood spots in drug development: pharmacokinetic considerations.

Authors:  Malcolm Rowland; Gary T Emmons
Journal:  AAPS J       Date:  2010-04-10       Impact factor: 4.009

4.  Pharmacokinetics of cyclosporin: influence of rate-duration profile of an intravenous infusion in renal transplant patients.

Authors:  S K Gupta; A Bakran; R W Johnson; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

5.  Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.

Authors:  Wai Johnn Sam; Lai San Tham; Michael J Holmes; Marion Aw; Seng Hock Quak; Kang Hoe Lee; Seng Gee Lim; Krishnan Prabhakaran; Sui Yung Chan; Paul C Ho
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  High-fat meals increase the clearance of cyclosporine.

Authors:  S K Gupta; L Z Benet
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

7.  The binding of cyclosporin A to human plasma: an in vitro microdialysis study.

Authors:  H Yang; W F Elmquist
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

8.  Generalized pharmacokinetic modeling for drugs with nonlinear binding: I. Theoretical framework.

Authors:  W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

Review 9.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Cyclosporin clinical pharmacokinetics.

Authors:  A Fahr
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.